494 related articles for article (PubMed ID: 33892201)
1. Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: Improved understanding and new strategic approach with sargramostim.
Chu S; McCormick TS; Lazarus HM; Leal LO; Ghannoum MA
Clin Immunol; 2021 Jul; 228():108731. PubMed ID: 33892201
[TBL] [Abstract][Full Text] [Related]
2. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients.
Miceli MH; Churay T; Braun T; Kauffman CA; Couriel DR
Mycopathologia; 2017 Jun; 182(5-6):495-504. PubMed ID: 28124219
[TBL] [Abstract][Full Text] [Related]
4. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
6. Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial.
Wan L; Zhang Y; Lai Y; Jiang M; Song Y; Zhou J; Zhang Z; Duan X; Fu Y; Liao L; Wang C
J Clin Oncol; 2015 Dec; 33(34):3999-4006. PubMed ID: 26392095
[TBL] [Abstract][Full Text] [Related]
7. Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Hussein AM; Ross M; Vredenburgh J; Meisenberg B; Hars V; Gilbert C; Petros WP; Coniglio D; Kurtzberg J; Rubin P
Eur J Haematol; 1995 May; 54(5):281-7. PubMed ID: 7781752
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation.
Eksioglu EA; Kielbasa J; Eisen S; Reddy V
Cytotherapy; 2011 Aug; 13(7):888-96. PubMed ID: 21609205
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease.
Safdar A; Rodriguez G; Zuniga J; Al Akhrass F; Georgescu G; Pande A
Acta Haematol; 2013; 129(1):26-34. PubMed ID: 23038157
[TBL] [Abstract][Full Text] [Related]
10. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.
Dvorak CC; Steinbach WJ; Brown JM; Agarwal R
Bone Marrow Transplant; 2005 Oct; 36(7):621-9. PubMed ID: 16044133
[TBL] [Abstract][Full Text] [Related]
11. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
Peters BG; Adkins DR; Harrison BR; Velasquez WS; Dunphy FR; Petruska PJ; Bowers CE; Niemeyer R; McIntyre W; Vrahnos D; Auberry SE; Spitzer G
Bone Marrow Transplant; 1996 Jul; 18(1):93-102. PubMed ID: 8832001
[TBL] [Abstract][Full Text] [Related]
12. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
13. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
15. Invasive fungal infection caused by Blastobotrys mokoenaii in an immunocompromised patient with acute myeloid leukemia: A case report.
Shiomi I; Makuuchi Y; Noura I; Kakuno S; Niki M; Kaimi Y; Ido K; Sakatoku K; Kuno M; Takakuwa T; Okamura H; Nishimoto M; Nakashima Y; Nakamae M; Kakeya H; Kohashi K; Hino M; Nakamae H
J Infect Chemother; 2024 Jun; 30(6):557-561. PubMed ID: 38092335
[TBL] [Abstract][Full Text] [Related]
16. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
J Microbiol Immunol Infect; 2016 Aug; 49(4):567-74. PubMed ID: 25735797
[TBL] [Abstract][Full Text] [Related]
18. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
19. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Lazarus HM; Ragsdale CE; Gale RP; Lyman GH
Front Immunol; 2021; 12():706186. PubMed ID: 34484202
[TBL] [Abstract][Full Text] [Related]
20. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
